Sunshine Biopharma (SBFM) Other Operating Expenses (2016 - 2025)

Sunshine Biopharma's (SBFM) quarterly Other Operating Expenses came in at -$7.0 in Q4 2025, up 99.93% quarter-over-quarter from -$10250.0 in Q3 2025.

Analysis

Sunshine Biopharma (SBFM) Other Operating Expenses (2016 - 2025) Analysis & Trends

Sunshine Biopharma (SBFM) has reported Other Operating Expenses for 2 consecutive years, with -$7.0 the latest figure, recorded in Q4 2025.

For the quarter ending Q4 2025, Other Operating Expenses changed N/A year-over-year to -$7.0; the trailing twelve-month figure through Jun 2026 stood at -$10257.0 (changed N/A YoY), and the FY2025 full-year result was -$10257.0, changed N/A from the prior year.
Other Operating Expenses climbed to -$7.0 in Q4 2025 per SBFM's latest filing, from -$10250.0 in the prior quarter.
Across five years, Other Operating Expenses topped out at -$7.0 in Q4 2025 and bottomed at -$10250.0 in Q3 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Teva Pharmaceutical Industries	42.61 Bn	38.95 Bn	2.15 Bn
2	Viatris	19.18 Bn	18.30 Bn	1.46 Bn
3	Dr Reddys Laboratories	9.85 Bn	9.68 Bn	396.53 Mn
4	Amneal Pharmaceuticals	5.48 Bn	5.35 Bn	334.51 Mn
5	Bausch Health Companies	2.36 Bn	518.87 Mn	2.10 Bn
6	Alvotech	1.50 Bn	1.36 Bn	2.56 Mn
7	Ani Pharmaceuticals	1.49 Bn	1.13 Bn	165.89 Mn
8	Amphastar Pharmaceuticals	994.21 Mn	704.09 Mn	93.47 Mn
9	Fennec Pharmaceuticals	405.56 Mn	364.31 Mn	17.15 Mn
10	Sunshine Biopharma	1.56 Mn	-12.19 Mn	2.43 Mn

Historic Data

Download Data